武漢佰樂博代理：Research Grade Telisotuzumab

貨號：DHC34203

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75316.html

產(chǎn)品購買聯(lián)系方式：027-65279366

產(chǎn)品介紹：Telisotuzumab (ABT-700)是一種人源化重組二價抗體，針對肝細胞生長因子受體（MET）的治療性抗體，可以高親和力結(jié)合c-Met并抑制c-Met信號傳導(dǎo)。Telisotuzumab具有抗腫瘤活性。

通用名：Telisotuzumab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：ABBV-399, ABT-700-vcMMAE, ABT-700, hz224G11

靶點;物種：Human MET/c-Met/HGFR

種類：Humanized

受體鑒定：IgG1-kappa

CAS: 1781223-80-0

參考文獻：

A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). PMID: 33221175

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. PMID: 36288547

Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors. PMID: 33675179

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. PMID: 35005654

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. PMID: 30285518